Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kissei Makes Full Foray into IBD Arena with Rectabul, Set to Enrich “Unmet Needs” Portfolio
February 27, 2018
- Daiichi Sankyo to Set Up Specialty Marketing Unit for Oncology Products
February 27, 2018
- Sumitomo Dainippon, JCR Ink License Pact for BBB-Based CNS Drug Candidate
February 27, 2018
- Kyowa Kirin’s Burosumab Earns Conditional Approval in Europe
February 27, 2018
- Sumitomo Dainippon Sues 15 More Companies over Latuda Patent
February 27, 2018
- Liquid Tank Exploded at Kitasato Daiichi Sankyo Vaccine, No Pathogens Escaped
February 27, 2018
- 1st–in-Human Trial Begins for ADC DS-1062 in NSCLC: Daiichi Sankyo
February 26, 2018
- Mitsubishi Tanabe to Complete PIII for Plant-Derived Flu Vaccine in April, Obtain Top-Line Data around Summer
February 26, 2018
- Nomura Picked as Next Chief of Sumitomo Dainippon, Vows to Build Peripheral Healthcare Biz
February 26, 2018
- Sid Singh Named as New President of GSK Consumer Healthcare Japan
February 26, 2018
- Diagnogreen Applied for Evaluation of Blood Flow: Daiichi Sankyo
February 23, 2018
- Fujifilm to Set Up New Manufacturing Facility for Liposome Drugs, Operation Launch Targeted in Feb. 2020
February 23, 2018
- Pfizer Japan No Longer Disclosing Biosimilar Development Status for “Competitive Reasons”
February 23, 2018
- Sumitomo Dainippon’s iPSC-Based Parkinson’s Therapy Set for IIT Launch in FY2018
February 22, 2018
- Nippon Kayaku’s Novel Paclitaxel Form in Breast Cancer PII after PIII Miss
February 22, 2018
- Takeda, Wave Ink Antisense Pact for Neurological Diseases
February 22, 2018
- Novartis Japan Chief on Rare Paternity Leave, Looks to Lead by Example
February 22, 2018
- Bristol-Myers Japan Taps Ex-AZ Exec Hashigami as Development Chief
February 21, 2018
- Taniuchi Appointed as Santen President and COO
February 21, 2018
- Aducanumab Trial Tweak “Common Decision” to Boost Statistical Confidence: Biogen CEO
February 21, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…